Ansun BioPharma is focused on developing innovative therapeutics to address unmet medical needs in the treatment of cancer and viral infections. One of their key technologies is DAS181, a first-in-class host-directed recombinant sialidase protein derived from *Actinomyces viscosus*. This therapeutic agent is designed to cleave sialic acids on the surface of epithelial cells in the human respiratory tract, which are essential for the entry of various respiratory viruses, including influenza and parainfluenza. By removing these sialic acids, DAS181 aims to block viral entry and provide a novel mechanism for treating respiratory viral infections, particularly in immunocompromised patients.

In addition to their work on viral infections, Ansun BioPharma is also developing multi-modality anti-solid tumor platforms to tackle the challenges posed by solid tumors, especially those lacking driver oncogenes or high mutational burdens. These tumors often evade immune surveillance through mechanisms such as hyper sialylation and immune checkpoint upregulation. Ansun's approach involves targeting both tumor and immune cells across various checkpoints, from innate to adaptive immunity, to restore effective immune responses and enhance therapeutic outcomes for cancer patients.

United States

Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.

Cancer

Digestive System Diseases

Infectious Diseases

Ansun BioPharma

Human parainfluenza viruses

Influenza

DAS181

Biologics

Breast cancer

Colorectal cancer

Melanoma

Ansun Drug #3

Cell Therapies

Solid tumor/s

Ansun Drug #2

CAR-T Immunotherapy

California - South

California

Small Molecule Pharmaceuticals

Viral Therapies/Virotherapies

Therapeutic

Ansun BioPharma

Company Details